Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Free Cash Flow: 2010-2025

Historic Free Cash Flow for Arrowhead Pharmaceuticals (ARWR) over the last 15 years, with Sep 2025 value amounting to $13.0 million.

  • Arrowhead Pharmaceuticals' Free Cash Flow rose 108.03% to $13.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $156.9 million, marking a year-over-year increase of 125.96%. This contributed to the annual value of $156.9 million for FY2025, which is 125.96% up from last year.
  • Latest data reveals that Arrowhead Pharmaceuticals reported Free Cash Flow of $13.0 million as of Q3 2025, which was up 108.26% from -$157.1 million recorded in Q2 2025.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Free Cash Flow peaked at $454.8 million during Q1 2025, and registered a low of -$186.5 million during Q4 2023.
  • For the 3-year period, Arrowhead Pharmaceuticals' Free Cash Flow averaged around -$60.3 million, with its median value being -$126.5 million (2024).
  • Its Free Cash Flow has fluctuated over the past 5 years, first surged by 922.94% in 2021, then plummeted by 214.78% in 2022.
  • Quarterly analysis of 5 years shows Arrowhead Pharmaceuticals' Free Cash Flow stood at -$67.1 million in 2021, then crashed by 70.57% to -$114.4 million in 2022, then crashed by 62.98% to -$186.5 million in 2023, then rose by 17.54% to -$153.8 million in 2024, then soared by 108.03% to $13.0 million in 2025.
  • Its Free Cash Flow stands at $13.0 million for Q3 2025, versus -$157.1 million for Q2 2025 and $454.8 million for Q1 2025.